awmsg logo



dasatinib (Sprycel®)


Reference No. 103

Publication date:
18/01/2008


Appraisal information

dasatinib (Sprycel®) film-coated tablet


Company: Bristol-Myers Squibb Pharmaceuticals Ltd
BNF category: Malignant disease and immunosupression
NMG meeting date: 13/11/2007
AWMSG meeting date: 11/12/2007
   
   
Submission Type: Full Submission
Status: Superseded
Advice No: 1307
Ministerial ratification: 16/01/2008

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

AWMSG ADVICE SUPERSEDED BY NICE GUIDANCE (TA241) NICE GUIDANCE ISSUED JANUARY 2012 (Refer to NICE website for full guidance on NICE recommendations, including any specific restrictions on the use of the technology) Dasatinib (Sprycel®) is recommended for restricted use within NHS Wales for the treatment of adults with chronic phase chronic myeloid leukaemia (CML) and accelerated phase CML where there is resistance or intolerance to prior therapy including imatinib mesilate. The use of dasatinib for blast phase is not recommended. Resistance to imatinib is defined in accordance with the European LeukaemiaNet criteria and on completion of mutation analysis. Intolerance is defined as a patient experiencing prior grade 3/4 toxicity, in accordance with the National Cancer Institute Common Toxicity Criteria, to imatinib despite receiving the lowest clinically effective dose. Dasatinib (Sprycel®) should only be initiated by specialists experienced in the treatment of chronic myeloid leukaemia. Dasatinib (Sprycel®) is not presently recommended for shared care.
Final Appraisal Recommendation (FAR)
Download